Story perspectives

MD Anderson and Myriad Partner to Revolutionize Cancer Treatment

1/8/2025

50 11

Summary

Story summary

MD Anderson Cancer Center and Myriad Genetics have joined forces in a groundbreaking five-year partnership to assess Myriad's molecular residual disease (MRD) assay. This collaboration promises to revolutionize cancer treatment by studying the test's effectiveness across different cancers, ultimately aiming to enhance patient outcomes. MD Anderson will spearhead patient enrollment and data analysis, while Myriad offers essential funding and testing support.

1 of 1

Story summary

MD Anderson Cancer Center and Myriad Genetics have joined forces in a groundbreaking five-year partnership to assess Myriad's molecular residual disease (MRD) assay. This collaboration promises to revolutionize cancer treatment by studying the test's effectiveness across different cancers, ultimately aiming to enhance patient outcomes. MD Anderson will spearhead patient enrollment and data analysis, while Myriad offers essential funding and testing support.